Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

09/20/2021 | 11:07am EDT

KENILWORTH, N.J. - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of the full results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract #LBA2). These data were also simultaneously published in the New England Journal of Medicine. This is the first combination regimen with an anti-PD-1/PD-L1 therapy to improve overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to chemotherapy with or without bevacizumab as a first-line treatment of persistent, recurrent or metastatic cervical cancer.

KEYTRUDA plus chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with or without bevacizumab (KEYTRUDA plus chemo +/- bev) reduced the risk of death by one-third, or 33% (HR=0.67 [95% CI, 0.54-0.84]; p

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about MERCK & CO., INC.
01:54aMERCK : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisi..
MT
10/20MERCK : British Government Secures COVID-19 Antivirals from Merck & Co., Pfizer
MT
10/20MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ (..
BU
10/20U.K. in Agreements for Merck/Ridgeback, Pfizer Covid-19 Antivirals in Development
DJ
10/20MERCK : to Voluntarily Recall About 22,000 Cubicin Vials Due to Presence of Glass Particle..
MT
10/20MERCK : WHO Program To Acquire Merck & Co.'s COVID-19 Pill Under Aid Program
MT
10/19MERCK : Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, ..
BU
10/19MERCK : WHO Program Aims to Secure COVID-19 Antiviral Drugs for Poorer Nations for $10 per..
MT
10/19Health Care Stocks Adding to Tuesday Recovery in Late Trade
MT
10/19WALL STREET STOCK EXCHANGE : Earnings season continues to deliver
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 165 M - -
Net income 2021 13 308 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 17,1x
Yield 2021 3,20%
Capitalization 205 B 205 B -
EV / Sales 2021 4,63x
EV / Sales 2022 4,09x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 81,07 $
Average target price 94,74 $
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-0.89%205 219
JOHNSON & JOHNSON4.07%431 385
ROCHE HOLDING AG15.84%337 562
NOVO NORDISK A/S57.04%239 813
PFIZER, INC.14.34%235 986
ELI LILLY AND COMPANY44.35%219 674